Literature DB >> 32594931

Dopamine D3 partial agonists in the treatment of psychosis and substance use disorder comorbidity: a pharmacological alternative to consider?

Daniel Hernández-Huerta1, Jessenia Morillo-González1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32594931     DOI： 10.1017/S1092852920001510

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


× No keyword cloud information.
  2 in total

1.  Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.

Authors:  Pierre-Michel Llorca; Philippe Nuss; Éric Fakra; Isabelle Alamome; Dominique Drapier; Wissam El Hage; Renaud Jardri; Stéphane Mouchabac; Marc Rabbani; Nicolas Simon; Marie-Noëlle Vacheron; Jean-Michel Azorin
Journal:  BMC Psychiatry       Date:  2022-05-28       Impact factor: 4.144

2.  Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series.

Authors:  Juan D Duque-Yemail; Juan Carlos Avila
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-13       Impact factor: 2.989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.